Bicalutamide and Flutamide, Each in Combination with Luteinizing Hormone‐Releasing Hormone Analogs, in Advanced Prostate Cancer: Exploratory Analysis of Impact of Extent of Disease by Bone Scan on Outcome
- 1 July 2000
- journal article
- Published by Wiley in The Prostate Journal
- Vol. 2 (3) , 137-145
- https://doi.org/10.1046/j.1525-1411.2000.23003.x
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trialUrology, 1997
- Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapyUrology, 1996
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancerUrology, 1995
- Current status of combined androgen blockade: optimal therapy for advanced prostate cancer [published erratum appears in J Clin Endocrinol Metab 1995 Jul;80(7):2056]Journal of Clinical Endocrinology & Metabolism, 1995
- Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)Urology, 1993
- Independent Prognostic Factors in Patients With Metastatic (Stage D2) Prostate CancerJAMA, 1991
- Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study GroupJAMA, 1991
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgensThe Prostate, 1983
- Whither pelvic lymphadenectomy in prostatic cancer?The Prostate, 1982